We have located links that may give you full text access.
12-month Continuation of the Etonogestrel Implant in Adolescents with Polycystic Ovary Syndrome.
Journal of Pediatric and Adolescent Gynecology 2020 September 10
STUDY OBJECTIVE: Describe why adolescents with Polycystic Ovary Syndrome (PCOS) chose the etonogestrel (ENG) contraceptive implant, determine the 12-month continuation rate and characterize factors related to discontinuation.
DESIGN: Setting, and Participants: Retrospective chart review of adolescents seen at a tertiary care children's hospital between July 1, 2008 and August 30, 2019 with PCOS diagnosis confirmed per NIH criteria and ≥ 12-month ENG follow-up.
INTERVENTIONS AND MAIN OUTCOME MEASURES: Demographic characteristics, reasons for ENG insertion and removal, and information on other hormonal/contraceptive therapies were collected. Patients were categorized as ENG continuers (use ≥ 12 months) or discontinuers (removed <12 months) and groups were compared.
RESULTS: Ninety-six patients met inclusion criteria (age 17.7±2.2 years, BMI 34.8±8 kg/m2 ). Reasons for ENG were documented in 74% (51% contraception, 32% ease of use, 15% other, 13% estrogen avoidance). 27% had never been sexually active and 67% had prior sexual activity. Treatments prior to ENG placement included 74% combined hormonal contraception, 20% medroxyprogesterone acetate withdrawal and 17% depot medroxyprogesterone. 77% continued ENG at 12 months. Top reasons for discontinuation were bleeding (41%), concern for weight gain (23%) and mood changes (18%). No pre-implant characteristics were independently predictive of continuation, although 100% of patients with type 2 diabetes (N=11) continued. Patients who sought additional care including phone calls (41% vs 12%, p=0.006) and clinic visits (64% vs 20%, p<0.001) were more likely to discontinue.
CONCLUSIONS: ENG implant was well tolerated in adolescents with PCOS and was similar to published 12-month continuation rates.
DESIGN: Setting, and Participants: Retrospective chart review of adolescents seen at a tertiary care children's hospital between July 1, 2008 and August 30, 2019 with PCOS diagnosis confirmed per NIH criteria and ≥ 12-month ENG follow-up.
INTERVENTIONS AND MAIN OUTCOME MEASURES: Demographic characteristics, reasons for ENG insertion and removal, and information on other hormonal/contraceptive therapies were collected. Patients were categorized as ENG continuers (use ≥ 12 months) or discontinuers (removed <12 months) and groups were compared.
RESULTS: Ninety-six patients met inclusion criteria (age 17.7±2.2 years, BMI 34.8±8 kg/m2 ). Reasons for ENG were documented in 74% (51% contraception, 32% ease of use, 15% other, 13% estrogen avoidance). 27% had never been sexually active and 67% had prior sexual activity. Treatments prior to ENG placement included 74% combined hormonal contraception, 20% medroxyprogesterone acetate withdrawal and 17% depot medroxyprogesterone. 77% continued ENG at 12 months. Top reasons for discontinuation were bleeding (41%), concern for weight gain (23%) and mood changes (18%). No pre-implant characteristics were independently predictive of continuation, although 100% of patients with type 2 diabetes (N=11) continued. Patients who sought additional care including phone calls (41% vs 12%, p=0.006) and clinic visits (64% vs 20%, p<0.001) were more likely to discontinue.
CONCLUSIONS: ENG implant was well tolerated in adolescents with PCOS and was similar to published 12-month continuation rates.
Full text links
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app